Journal Article Review Epublish 1 citation
PubMed: 39409909 DOI: 10.3390/cancers16193288
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies.
Cancers (Basel) 16(19)
Authors: Kevin Guanwen Shim, Rafael Fonseca
Affiliations
- Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
Abstract
Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial and real-world data, these therapies have demonstrated high rates of deep clinical response, and some are now approved for second-line treatment for relapsed MM. The deep and sustained clinical responses these therapies are capable of inducing will require sophisticated response monitoring to provide meaningful information for patient care. Obtaining measurable residual disease (MRD) negativity has been validated as an independent positive prognostic marker for progression-free survival (PFS) and overall survival (OS) in both newly diagnosed and relapsed refractory patients with multiple myeloma. Assessment for MRD negativity was performed in all of the trials for FDA-approved TRT. Here, we summarize pertinent data for MRD assessment following TRT in MM and provide a rationale and structured framework for conducting MRD testing post TRT.
MeSH
Cells, Research Design, Multiple Myeloma, Therapeutics, T-Lymphocytes, Antibodies, Bispecific